New Journey Health Technology Group (002219) Fair Value & Analysis
Healthcare · CN · Market cap 6.9B CNY
Fair value as of: Jul 22, 2026
From 25 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from ¥0.7500 to ¥0.2700 (−64.0%) since Jun 25, 2026. Share price +18.9% over the past month.
Below-average quality, and screening another 87% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥0.3100). The favourable scenario is already priced in.
- Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (¥0.1500 to ¥0.3100) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range ¥1.69 – ¥5.69 · fair‑value band ¥0.1500 – ¥0.3100 · the ¥2.14 price screens above the ¥0.2700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
New Journey Health Technology Group (002219) currently trades at ¥2.14, while our model-based Fair Value estimate is ¥0.2700, implying the stock looks roughly 87.4% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, New Journey Health Technology Group generated revenue of 3.0B CNY at a net margin of 0.9%. Revenue declined 9.6% year over year. It earns a return on equity of 1.4%. Net debt stands at 995M CNY. Fundamentals as of Jul 22, 2026
Our scenario range runs from ¥0.1500 (bear case) to ¥0.3100 (bull case); at ¥2.14, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -87%, 002219 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (¥0.8100) versus Earnings-Based (¥0.1100). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 43
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
New Journey Health Technology Group Co.,LTD, together with its subsidiaries, provides medical services and pharmaceuticals products in China and internationally. The company operates regional medical centers to treat aging diseases, such as tumors, cardiovascular, cerebrovascular, and orthopedics.
Full company description
New Journey Health Technology Group Co.,LTD, together with its subsidiaries, provides medical services and pharmaceuticals products in China and internationally. The company operates regional medical centers to treat aging diseases, such as tumors, cardiovascular, cerebrovascular, and orthopedics. It is also involved in the research, development, production, and sale of medicines comprising Duyiwei capsules, Ginsengqi Schisandra tablets, Maiping tablets, Prosta Antong tablets, Gongzhongning capsules, Wuhu San, Wei Funing capsules, and other proprietary Chinese medicine products. In addition, it engages in Chinese herbal medicine planting; investment management; retail business; wholesale trading activities; and provision of resident services. The company was formerly known as Hengkang Medical Group Co.,Ltd. New Journey Health Technology Group Co.,LTD was founded in 2001 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
New Journey Health Technology Group reported revenue of ¥3.1B in FY2025 versus ¥3.0B in FY2021, a compound +0.3%/yr. Reported net income was ¥30.9M in FY2025.
002219 screens 87% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare New Journey Health Technology Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is New Journey Health Technology Group (002219) overvalued or undervalued?
What is the fair value of 002219?
What is the quality score of 002219?
What is the revenue of New Journey Health Technology Group (002219)?
What is the net profit margin of 002219?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track New Journey Health Technology Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.